Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | TTR | P02766 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 8/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4645309 | 0.83 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ATTRMAPT | |
| SCHEMBL27916746 | 0.81 | MAPT (0.57) | SMN1; SMN2NPC1RAB9ATTRMAPT | |
| SCHEMBL11107245 | 0.79 | TTR (0.54) | SMN1; SMN2NPC1RAB9ATTRMAPT | |
| SCHEMBL22323640 | 0.76 | MAPT (0.44) | SMN1; SMN2NPC1RAB9ATTRMAPT | |
| Acetic Acid Methyl Ester SCHEMBL11739457 | 0.75 | MAOA (0.54) | SMN1; SMN2NPC1RAB9ATTRMAPT | |
| SCHEMBL11101186 | 0.74 | TTR (0.72) | SMN1; SMN2NPC1RAB9ATTRMAPT | |
| SCHEMBL3959473 | 0.74 | MAPT (0.69) | SMN1; SMN2NPC1RAB9ATTRMAPT | |
| SCHEMBL11233502 | 0.74 | TTR (0.55) | SMN1; SMN2TTRMAPTMEN1KMT2A | |
| SCHEMBL11000611 | 0.73 | KDM4E (0.59) | SMN1; SMN2TTRMAPTMEN1KMT2A | |
| SCHEMBL11363990 | 0.72 | TTR (0.53) | SMN1; SMN2NPC1TTRMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210230178-A1 | TRIOXACARCIN ANALOGS AND DIMERS AS POTENT ANTICANCER AGENTS | WILLIAM MARSH RICE UNIVERSITY (US) | 2021-07-29 | — | — | US | disclosed |
| WO-2019036537-A1 | TRIOXACARCIN ANALOGS AND DIMERS AS POTENT ANTICANCER AGENTS | WILLIAM MARSH RICE UNIVERSITY (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230178-A1 | TRIOXACARCIN ANALOGS AND DIMERS AS POTENT ANTICANCER AGENTS | ANXA5, HCCS, BAX | SMN1; SMN2 3346/4885NPC1 648/4885RAB9A 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.